Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics


Eloxx Pharmaceuticals, Inc. (ELOX): $1.85

0.09 (+5.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ELOX Stock Price Chart Interactive Chart >

Price chart for ELOX

ELOX Price/Volume Stats

Current price $1.85 52-week high $6.77
Prev. close $1.76 52-week low $1.18
Day low $1.74 Volume 482,000
Day high $1.89 Avg. volume 953,315
50-day MA $1.49 Dividend yield N/A
200-day MA $2.59 Market Cap 159.48M

Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio


Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.


ELOX Latest News Stream


Event/Time News Detail
Loading, please wait...

ELOX Latest Social Stream


Loading social stream, please wait...

View Full ELOX Social Stream

Latest ELOX News From Around the Web

Below are the latest news stories about Eloxx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELOX as an investment opportunity.

Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations

WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene for whom there are no effective disease modifying thera

Yahoo | September 9, 2021

Eloxx Pharmaceuticals Appoints Chief Medical Officer

Ali Hariri, M.D. to Lead Clinical Development Efforts for Company PipelineWATERTOWN, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing clinical development efforts for the company’s promising pipeline of therapies to treat rare diseases. Dr. Hariri will report to Vijay Modur, M.B.B.S., Ph.D., the company’s Head of Research and Development. Dr. Hariri was previously Se

Yahoo | September 8, 2021

Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)

Intrado Digital Media | August 16, 2021

Global Duchenne Muscular Dystrophy Drugs Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Akashi Therapeutics Inc, Capricor Therapeutics Inc, Biogen Inc, Antisense Therapeutics Ltd, Biophytis SAS, Beech Tree Labs Inc, CRISPR Therapeutics, BioMarin Pharmaceutical Inc, Bioleaders Corp, Catabasis Pharmaceuticals Inc, Eloxx Pharmaceuticals Inc, Fulcrum Therapeutics In

The report on Global Duchenne Muscular Dystrophy Drugs Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []

Jumbo News | July 23, 2021

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena P...

Benzinga | July 20, 2021

Read More 'ELOX' Stories Here

ELOX Price Returns

1-mo 17.09%
3-mo -11.06%
6-mo -42.37%
1-year -30.97%
3-year -88.37%
5-year -44.44%
YTD -53.52%
2020 -45.92%
2019 -38.72%
2018 50.13%
2017 185.31%
2016 -64.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.4786 seconds.